65 related articles for article (PubMed ID: 17764779)
41. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment.
Wachters FM; Groen HJ; Biesma B; Schramel FM; Postmus PE; Stigt JA; Smit EF
Br J Cancer; 2005 Jan; 92(1):15-20. PubMed ID: 15597104
[TBL] [Abstract][Full Text] [Related]
42. [Results of a Special Drug Use-Results Survey on Compliance to Tegafur/Uracil(UFT)Adjuvant Chemotherapy for Non-Small Cell Lung Cancer].
Koyama T; Funato Y; Yamaguchi Y; Oda M; Ito K
Gan To Kagaku Ryoho; 2015 Aug; 42(8):973-80. PubMed ID: 26321712
[TBL] [Abstract][Full Text] [Related]
43. Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.
Lilenbaum R; Wang X; Gu L; Kirshner J; Lerro K; Vokes E
J Clin Oncol; 2009 Sep; 27(27):4487-91. PubMed ID: 19704058
[TBL] [Abstract][Full Text] [Related]
44. Gemcitabine plus UFT combination chemotherapy as second- or third-line therapy in non-small cell lung cancer: a pilot study.
Nishimura N; Sugiura R; Ueda H; Ono H; Horinouchi H; Uchiyama N; Chohnabayashi N
J Med Invest; 2008 Aug; 55(3-4):260-6. PubMed ID: 18797141
[TBL] [Abstract][Full Text] [Related]
45. [Hand-foot syndrome associated with uracil/tegafur and docetaxel in a patient with lung cancer].
Kanaji N; Bandoh S
Nihon Kokyuki Gakkai Zasshi; 2007 Jun; 45(6):474-8. PubMed ID: 17644943
[TBL] [Abstract][Full Text] [Related]
46. [How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study].
Moro-Sibilot D; Barlesi F; Timsit JF; Debieuvre D; Fournel P; Gervais R; Mazieres J; Milleron B; Morin F; Perol M; Soria JC; Souquet PJ; Vergnenègre A; Zalcman G
Rev Mal Respir; 2008 Jan; 25(1):91-6. PubMed ID: 18288059
[TBL] [Abstract][Full Text] [Related]
47. Identification of adverse events that have a negative impact on quality of life in a clinical trial comparing docetaxel versus S-1 with cisplatin in lung cancer.
Aotani E; Hamano T; Gemma A; Takeuchi M; Takebayashi T; Kobayashi K
Int J Clin Oncol; 2016 Oct; 21(5):836-842. PubMed ID: 26879651
[TBL] [Abstract][Full Text] [Related]
48. No pharmacokinetic alteration of docetaxel following coadministration of aprepitant 3 h before docetaxel infusion.
Kaneta T; Fujita K; Akiyama Y; Kawara K; Sunakawa Y; Kawachi A; Shimada K; Sasaki Y
Cancer Chemother Pharmacol; 2014 Sep; 74(3):539-47. PubMed ID: 25053387
[TBL] [Abstract][Full Text] [Related]
49. Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients.
Cassileth BR; Rizvi N; Deng G; Yeung KS; Vickers A; Guillen S; Woo D; Coleton M; Kris MG
Cancer Chemother Pharmacol; 2009 Dec; 65(1):67-71. PubMed ID: 19421753
[TBL] [Abstract][Full Text] [Related]
50. Oral tegafur-uracil as a metronomic therapy in stage IVa and IVb cancer of the oral cavity.
Huang WY; Ho CL; Chao TY; Lee JC; Chen JH
Am J Otolaryngol; 2021; 42(6):103156. PubMed ID: 34242883
[TBL] [Abstract][Full Text] [Related]
51. Prognostic impact of cortactin in patients with hypopharyngeal cancer and its role for tegafur-uracil maintenance after adjuvant chemoradiotherapy.
Lien CF; Hwang TZ; Lin TM; Liu KW; Lin BS; Wang CC; Yang CC; Yeh SA; Hsieh MC
Am J Cancer Res; 2023; 13(11):5504-5512. PubMed ID: 38058839
[TBL] [Abstract][Full Text] [Related]
52. Factors affecting efficacy and safety of add-on combination chemotherapy for non-small-cell lung cancer: a literature-based pooled analysis of randomized controlled trials.
Inoue K; Narukawa M; Takeuchi M
Lung; 2012 Aug; 190(4):355-64. PubMed ID: 22350680
[TBL] [Abstract][Full Text] [Related]
53. Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
Califano R; Griffiths R; Lorigan P; Ashcroft L; Taylor P; Burt P; Lee L; Chittalia A; Harris M; Faivre-Finn C; Thatcher N; Blackhall F
Lung Cancer; 2011 Sep; 73(3):338-44. PubMed ID: 21296449
[TBL] [Abstract][Full Text] [Related]
54. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
[TBL] [Abstract][Full Text] [Related]
55. Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer.
Park SH; Choi SJ; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Cho EK; Shin DB; Hoon Lee J
Cancer; 2007 Feb; 109(4):732-40. PubMed ID: 17211861
[TBL] [Abstract][Full Text] [Related]
56. Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer.
Takayama K; Kawasaki M; Ninomiya K; Motohiro A; Fujita M; Watanabe K; Kajiki A; Iwami F; Miyazaki N; Izumi M; Hara N; Nakanishi Y;
Respirology; 2008 Jan; 13(1):103-7. PubMed ID: 18197918
[TBL] [Abstract][Full Text] [Related]
57. Phase II randomized study of weekly docetaxel alone or plus UFUR treatment in non-small cell lung cancer patients who failed previous chemotherapy.
Chou KT; Chen YM; Shih JF; Perng RP; Tsai CM; Whang-Peng J
Lung Cancer; 2008 Jan; 59(1):64-8. PubMed ID: 17764779
[TBL] [Abstract][Full Text] [Related]
58. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy.
Chen YM; Shih JF; Perng RP; Tsai CM; Whang-Peng J
Chest; 2006 Apr; 129(4):1031-8. PubMed ID: 16608954
[TBL] [Abstract][Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
